Inactive Instrument
Quotes Synta Pharmaceuticals Corp. Nasdaq
Stocks
US87162T2069
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 11-06 | HEALTH ROUNDS-New blood test matches gold standard for liver disease diagnosis | RE |
| 11-05 | Madrigal Pharmaceuticals, Inc. Announces Real-World Data Demonstrating Improvements With Rezdiffra | CI |
Stock exchange
Nasdaq- $
-
0
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
| MDGL | 427.39USD | +0.51% | 189M $ | ||
| MDGL | 427.38USD | +0.61% | 6.86M $ | ||
| YDO1 | 386.20EUR | +0.08% | 19.31K € | ||
| YDO1 | 387.50EUR | +0.94% | 4.26K € | ||
| YDO1 | 387.50EUR | +0.81% | 0 € | ||
| YDO1 | 387.10EUR | +0.81% | 0 € | ||
| 1MDGL | 440.10EUR | -1.30% | 0 € | ||
| YDO1 | 379.40EUR | -2.57% | 0 € |
Basic data
Market Cap (USD)
9,928,082,075
Net sales (USD)
958,403,000
Free-Float
94.2%
Free-Float capitalization (USD)
9,352,718,118
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | 0.00% | - | - | 9.93B | ||
| -2.69% | -0.48% | +53.97% | +66.82% | 66.33B | ||
| -0.92% | +7.67% | +12.64% | +93.22% | 60.62B | ||
| 0.00% | +0.39% | +22.34% | +89.58% | 55.5B | ||
| +0.14% | +2.35% | +13.86% | +111.94% | 47.58B | ||
| -2.21% | -2.47% | +20.18% | +28.81% | 43.69B | ||
| -2.30% | -10.40% | +154.30% | +707.36% | 37.27B | ||
| +2.15% | +1.42% | +14.58% | +48.71% | 36.57B | ||
| -2.32% | -2.24% | +76.50% | +56.02% | 32.22B | ||
| +2.62% | +5.90% | -37.29% | +386.59% | 26.58B | ||
| Average | -0.61% | +0.05% | +36.79% | +176.56% | 42B | |
| Weighted average by Cap. | -0.83% | +0.20% | +36.63% | +152.23% |
Historical Quotes: Synta Pharmaceuticals Corp.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Price Extremes
- Stock Market
- Stocks
- MDGL Stock
- Stock
- Quotes Synta Pharmaceuticals Corp.
Select your edition
All financial news and data tailored to specific country editions
















